Stanford Study Finds Fasting Diet Eases Crohn's Disease Symptoms

LOS ANGELES, CA – January 28, 2026 – For the millions of people worldwide battling Crohn's disease, a new frontier in treatment may be opening up, one that relies not on a pill but on a plate. A groundbreaking independent study from Stanford University, published in the prestigious journal Nature Medicine, has provided compelling clinical evidence that a periodic, five-day Fasting Mimicking Diet (FMD) can significantly improve symptoms and induce remission in patients with mild-to-moderate Crohn's disease.

The findings represent a major victory for the growing 'Food as Medicine' movement and for L-Nutra, the nutri-technology company whose fasting-mimicking technology formed the basis of the dietary intervention. The study offers a scientifically rigorous, non-pharmacologic approach for a condition where patients have long sought effective alternatives to conventional drug therapies.

A Scientific Breakthrough in Detail

The randomized controlled trial evaluated adults with mild-to-moderate Crohn's who followed a five-day FMD protocol once a month for three months. This plant-based, calorie-restricted diet is designed to trick the body into a fasting state while still providing micronutrients. For the other 25 days of the month, participants returned to their normal eating habits. Crucially, all participants continued their standard medical treatments, positioning the diet as an adjunctive, rather than replacement, therapy.

The results were striking. Compared to a control group that continued their baseline diet, the FMD group demonstrated significantly better outcomes:

• Clinical Response: Nearly 70% of participants in the FMD group achieved a clinical response, meaning a significant reduction in their disease symptoms.
• Clinical Remission: More than 60% of the FMD group achieved clinical remission, a state of minimal to no disease activity.
• Rapid Results: For many, the benefits appeared quickly, with a majority of responders showing improvement after just the first five-day cycle.

Beyond subjective symptom improvement, the study tracked objective biological markers of inflammation. Participants on the FMD saw a meaningful reduction in fecal calprotectin, a key inflammatory protein used to monitor Crohn's activity, while the control group did not. Exploratory analysis also revealed changes in immune-related gene expression consistent with reduced disease activity.

One of the most compelling findings emerged from a subgroup of patients who were not taking any Crohn's medications at the start of the study. In this group, the clinical response rate for those on the FMD was more than double that of the controls (76.9% vs. 33.3%), highlighting its potential relevance for a population with very few FDA-approved treatment options.

A New Horizon for Patients and Doctors

For decades, the standard of care for Crohn's disease has centered on powerful anti-inflammatory drugs, including corticosteroids and biologics. While these medications can be life-changing, they often come with a risk of significant side effects, may lose effectiveness over time, and leave many patients searching for complementary options to manage their health.

"Nutrition has long been recognized in medicine, but rarely evaluated or deployed with the rigor expected of a therapeutic intervention," said William Hsu, MD, Chief Medical Officer of L-Nutra. "These findings demonstrate that when nutrition is scientifically designed, protocol-driven, and grounded in human cellular physiology, it can function as a credible adjunctive therapeutic approach."

Independent gastroenterologists not involved in the study note that patients frequently ask about dietary changes, but clinicians have been hampered by a lack of high-quality evidence. This study, published in a top-tier journal, provides the kind of data needed to have a more informed conversation.

"This is the type of evidence we've been waiting for," commented one clinical dietitian specializing in inflammatory bowel disease (IBD). "It gives us a structured, evidence-based protocol to discuss with patients. However, it's critical that this is done under medical supervision. Crohn's patients are at risk for malnutrition, and any restrictive diet must be managed carefully by a professional healthcare team."

The Rise of 'Food as Medicine'

The Stanford study serves as a landmark validation for the broader 'Food as Medicine' movement, which posits that specific nutritional interventions can be used to prevent and treat disease. While the concept is ancient, its modern application has been challenged by a lack of scientific rigor and skepticism from the medical establishment.

L-Nutra has positioned itself at the forefront of this movement, translating longevity science into what it calls 'nutri-technology'. The company holds over 200 patents and has collaborated with 18 academic institutions on dozens of clinical trials to validate its FMD technology, not just for longevity but for specific disease states.

"For decades, we have been building toward a future where nutrition is no longer peripheral to healthcare, but foundational to it," said Joseph Antoun, MD, PhD, Chairman and CEO of L-Nutra. "Independent clinical research like this reinforces the role that evidence-based food technologies can play alongside standard care, particularly for patients facing limited options."

This new data strengthens L-Nutra's mission to have medically supervised nutrition recognized and integrated into standard care. The company's strategy involves a two-pronged approach: a consumer-facing brand, Prolon®, for general wellness, and a medical division, L-Nutra Health, which develops programs for specific conditions like diabetes and, now potentially, Crohn's disease.

From Lab to Market: The Path Forward

With strong scientific validation in hand, the next challenge is commercialization and accessibility. L-Nutra's recent Series D financing, led by Mubadala Investment Company, is already fueling a global expansion into the Middle East and North Africa. This study will undoubtedly become a cornerstone of its market strategy, providing the clinical proof needed to engage healthcare systems.

The ultimate hurdle will be convincing payers—insurance companies and national health systems—to cover the cost of FMD programs. This typically requires a high bar of evidence demonstrating not only efficacy but also long-term cost-effectiveness. Payers will want to see if using the FMD can reduce the need for expensive biologics, decrease hospitalizations, and ultimately lower the overall cost of care.

The path to widespread adoption will likely involve developing comprehensive, medically supervised programs that bundle the FMD product with dietitian support and physician oversight, making it a reimbursable therapeutic service rather than just a food product. While challenges remain, this study marks a pivotal moment, potentially shifting the paradigm of Crohn's management and empowering patients with a powerful new tool to reclaim control over their health.